Trials / Withdrawn
WithdrawnNCT00396240
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,294 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | |
| PROCEDURE | Initiatives to improve compliance |
Timeline
- Start date
- 2002-02-01
- First posted
- 2006-11-06
- Last updated
- 2009-03-26
Source: ClinicalTrials.gov record NCT00396240. Inclusion in this directory is not an endorsement.